Improvement of the immunogenicity of ESAT-6 via fusion with the dodecameric protein dodecin of Mycobacterium tuberculosis.
Dodecin
ESAT-6
Immunogenicity
Multimeric fusion protein
Mycobacterium tuberculosis
Journal
Microbial pathogenesis
ISSN: 1096-1208
Titre abrégé: Microb Pathog
Pays: England
ID NLM: 8606191
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
14
01
2021
revised:
21
03
2021
accepted:
22
03
2021
pubmed:
30
4
2021
medline:
22
6
2021
entrez:
29
4
2021
Statut:
ppublish
Résumé
Tuberculosis (TB) is a chronic infectious disease that creates a heavy medical burden worldwide. The only approved vaccine, Bacillus Calmette-Guérin (BCG), cannot fully protect adolescents and adults from TB. Therefore, there is an urgent need to develop an effective new vaccine. Previous studies have found that dodecin, a flavin-binding protein of Mycobacterium tuberculosis (Mtb), can form stable dodecamers and has the potential to improve the immunogenicity of Mtb antigens. In this study, we constructed the fusion protein dodecin-ESAT-6 and evaluated the immunogenicity of dodecin, ESAT-6, and dodecin-ESAT-6 separately. Our results showed that dodecin-ESAT-6 is a dodecameric protein that can withstand heat at 95 °C and under SDS-PAGE conditions. Dodecin-ESAT-6 increased the expression of the costimulatory molecules CD80, CD86, and major histocompatibility complex class II (MHC-II) on the surface of RAW264.7 macrophages. Mice immunized with dodecin-ESAT-6 exhibited higher percentages of antigen-specific CD4
Identifiants
pubmed: 33915207
pii: S0882-4010(21)00162-5
doi: 10.1016/j.micpath.2021.104890
pii:
doi:
Substances chimiques
Antigens, Bacterial
0
BCG Vaccine
0
Bacterial Proteins
0
Tuberculosis Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104890Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.